Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Up 128.7% in January

Clearmind Medicine Inc. (NASDAQ:CMND) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 100,877 shares, an increase of 128.7% from the December 31st total of 44,113 shares. Currently, 6.7% of the company’s stock are short sold. Based on an average trading volume of 193,471 shares, the short-interest ratio is presently 0.5 days. Based on an average trading volume of 193,471 shares, the short-interest ratio is presently 0.5 days. Currently, 6.7% of the company’s stock are short sold.

Clearmind Medicine Stock Down 11.8%

CMND stock traded down $0.30 during mid-day trading on Thursday, hitting $2.22. 37,248 shares of the company were exchanged, compared to its average volume of 128,123. Clearmind Medicine has a 12-month low of $1.74 and a 12-month high of $60.00. The firm has a market capitalization of $3.33 million, a P/E ratio of -0.08 and a beta of 1.36. The business has a fifty day simple moving average of $3.49 and a 200-day simple moving average of $25.66.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Clearmind Medicine stock. AdvisorShares Investments LLC lifted its position in shares of Clearmind Medicine Inc. (NASDAQ:CMND) by 9.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 224,378 shares of the company’s stock after acquiring an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 96.05% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a research report on Saturday, December 20th.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.